0.05Open0.05Pre Close0 Volume1 Open Interest7.50Strike Price0.00Turnover1020.23%IV893.42%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1530Delta0.2304Gamma15.22Leverage Ratio-0.0178Theta0.0000Rho2.33Eff Leverage0.0002Vega
Verrica Pharmaceuticals Stock Discussion
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
Friday, 6th December at 8:00 am
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its develop...
loading...
Buying some in speculation and feeling some green days ahead due to presese of signal of uptrend and thinnner negetive free cash flow shrinkage year round no risk no substantial rewards looks like 5 year bottom rebounding
loading...
WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptanc...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure
- Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists
WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing med...
No comment yet